Li Wu1,2, Jing Li3, Caixia Fu4, Bernd Kühn5, Xiaolin Wang6,7. 1. Institute of Biomedical Manufacturing and Life Quality Engineering, School of Mechanical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, China. fdwl525@163.com. 2. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. fdwl525@163.com. 3. Institute of Diagnostic and Interventional Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. 4. MR Application Development, Siemens Shenzhen Magnetic Resonance Ltd, Shenzhen, China. 5. MR Application Predevelopment, Siemens Healthcare, Erlangen, Germany. 6. Shanghai Institute of Medical Imaging, Shanghai, China. 7. Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Abstract
PURPOSE: To investigate the value of using diffusion-weighted imaging (DWI) and intravoxel incoherent motion DWI (IVIM-DWI) to assess the chemotherapy response of pancreatic cancer in an orthotopic mouse model. MATERIALS AND METHODS: Twenty-four BALB/C nu/nu mice in two groups (n = 12/group) with human pancreatic adenocarcinoma xenografts were dosed intravenously with saline (group 1) and gemcitabine (group 2). DWI with 3 b values (b = 50, 400 and 800 s/mm2) and IVIM-DWI with multiple b values (b = 0, 25, 50, 80, 100, 300, 500, 800 s/mm2) were performed on the day before and 1 and 10 days after the treatment. Regions of interest (ROI) were drawn and tumor ADC, Dslow, Dfast and fp values derived from the DWI and IVIM-DWI were compared between the two groups. At the day 28 after the treatment, the tumors were harvested for histologic analyses. RESULTS: The values of ADC and Dslow in the entire tumor region were significantly increased in gemcitabine-treated group in contrast to saline-untreated group at day 1 (1.88 ± 0.34 × 10-3 s/mm2 vs 1.45 ± 0.16 × 10-3 s/mm2, P = 0.028, and 1.74 ± 0.29 × 10-3 s/mm2 vs 1.34 ± 0.26 × 10-3 s/mm2, P =0.030), but Dfast and fp values were not significantly different. Immunohistochemical results showed that cell proliferation was significantly reduced (P < 0.001) and cell apoptosis (P < 0.001) significantly increased in gemcitabine group compared to saline group. MVD was not significantly different. CONCLUSION: Both ADC value and Dslow value can be used as early imaging marker to assess the early chemotherapy response of pancreatic cancer.
PURPOSE: To investigate the value of using diffusion-weighted imaging (DWI) and intravoxel incoherent motion DWI (IVIM-DWI) to assess the chemotherapy response of pancreatic cancer in an orthotopic mouse model. MATERIALS AND METHODS: Twenty-four BALB/C nu/nu mice in two groups (n = 12/group) with humanpancreatic adenocarcinoma xenografts were dosed intravenously with saline (group 1) and gemcitabine (group 2). DWI with 3 b values (b = 50, 400 and 800 s/mm2) and IVIM-DWI with multiple b values (b = 0, 25, 50, 80, 100, 300, 500, 800 s/mm2) were performed on the day before and 1 and 10 days after the treatment. Regions of interest (ROI) were drawn and tumor ADC, Dslow, Dfast and fp values derived from the DWI and IVIM-DWI were compared between the two groups. At the day 28 after the treatment, the tumors were harvested for histologic analyses. RESULTS: The values of ADC and Dslow in the entire tumor region were significantly increased in gemcitabine-treated group in contrast to saline-untreated group at day 1 (1.88 ± 0.34 × 10-3 s/mm2 vs 1.45 ± 0.16 × 10-3 s/mm2, P = 0.028, and 1.74 ± 0.29 × 10-3 s/mm2 vs 1.34 ± 0.26 × 10-3 s/mm2, P =0.030), but Dfast and fp values were not significantly different. Immunohistochemical results showed that cell proliferation was significantly reduced (P < 0.001) and cell apoptosis (P < 0.001) significantly increased in gemcitabine group compared to saline group. MVD was not significantly different. CONCLUSION: Both ADC value and Dslow value can be used as early imaging marker to assess the early chemotherapy response of pancreatic cancer.
Entities:
Keywords:
(IVIM); Diffusion-weighted MRI (DWI); Intravoxel incoherent motion; Pancreatic cancer
Authors: Natalie J Serkova; Kristine Glunde; Chad R Haney; Mohammed Farhoud; Alexandra De Lille; Elizabeth F Redente; Dmitri Simberg; David C Westerly; Lynn Griffin; Ralph P Mason Journal: Cancer Res Date: 2020-12-01 Impact factor: 13.312